Capricor Therapeutics, Inc.

CAPR Healthcare Biotechnology

Capricor Therapeutics, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $22.3 million, down 11.5% from fiscal 2023. In the quarter to June 2026, revenue fell 7.92%, EPS fell 22.8% and free cash flow fell 72.9%, each against the same quarter a year earlier.

6.88 0.59 −7.90%
Market cap
$434.3M
P/E
0.0×
Fwd P/E
−13.2×
Dividend yield
—
F-score
4/9
Altman Z
10.32
Beneish M
−2.61
Dividend safety
n/a

A Cash Flow Statement is a financial report that details the cash inflows and outflows of a company over a specific period. It is divided into three sections: operating activities, investing activities, and financing activities. This statement helps assess the company’s liquidity, solvency, and overall financial health. By tracking cash movements, it provides insights into the company's ability to generate cash to fund operations, pay debts, and invest in growth. Businesses and investors use it to evaluate the sustainability of a company's cash flow and its financial stability.

Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16
Net Income
(105.04) (40.47) (22.29) (29.02) (20.02) (13.66) (7.64) (15.19) 2.43 (18.81)
Depreciation & Amortization
1.89 1.43 1.07 0.53 0.25 0.14 0.17 0.16 0.14 0.13
Non Cash Items (Other)
21.14 9.83 7.37 4.65 2.70 1.95 0.70 1.73 (13.94) 3.46
Accounts Receivable Change
10.31 0.00 (9.82) (0.16) (0.39) 0.09 0.12 0.14 (0.12) (0.01)
Accounts Payable Change
— — 1.39 1.72 (0.15) 1.84 (0.27) (0.35) (1.54) 0.51
Change in payables and accrued liability
5.98 1.94 1.33 (0.51) 0.59 (0.01) (0.36) (0.07) 0.08 0.48
Change in other assets and liabilities
(4.09) (12.73) (3.25) 27.70 0.21 (0.41) 0.19 (0.28) (1.28) (0.21)
Operating Cash Flow
(69.81) (40.00) (25.60) 4.92 (16.81) (10.05) (6.82) (13.86) (14.23) (14.45)
Capital expenditures
248.87 92.26 (2.05) (3.36) (1.20) (0.55) 3.00 22.68 (0.03) (0.19)
Long-Term Investments Change (Net)
(151.39) (208.44) 7.16 (31.71) — 5.99 (3.00) (18.01) 5.01 (5.00)
Investing cash flow
97.48 (116.18) 5.11 (35.07) (1.20) 5.44 (3.00) 4.67 4.98 (5.19)
Repayment/Issuance of Debt (Net)
— — — — — 0.32 — — 0.50 4.75
Equity Repurchase (Common, Net)
248.89 152.77 25.58 4.87 20.23 33.06 9.18 6.85 11.08 13.88
Financing cash flow
248.89 152.77 25.58 4.87 20.23 33.38 9.18 6.85 11.58 18.63
Change in Cash
276.56 (3.41) 5.09 (25.28) 2.22 28.77 (0.65) (2.34) 2.33 (1.02)
Beginning Cash
11.29 14.69 9.60 34.89 32.67 3.90 4.55 6.88 4.55 5.57
Ending Cash
287.85 11.29 14.69 9.60 34.89 32.67 3.90 4.55 6.88 4.55
Stock Based Compensation
16.97 9.77 7.39 4.46 2.97 1.95 0.70 1.73 1.71 1.96
Dividends Paid (Common)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Cash/Marketcap
— 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Assets Liabilities Change (Total)
12.20 (10.78) (11.75) 28.75 0.26 1.51 (0.06) (0.55) (2.86) 0.76
Investments Change (Net)
(151.39) (208.44) 7.16 (31.71) — 5.99 (3.00) (18.01) 5.01 (5.00)
Issuance/Purchase of Shares
248.89 152.77 25.58 4.87 20.23 33.06 9.18 6.85 11.08 13.88
Other line items
Revenue per Employee
0.00 0.14 0.25 0.03 0.01 0.01 0.06 0.08 0.07 0.10

Fold the line items

In millions of $ except per-share values · columns are period end dates